Targeted toxicological screening for acidic, neutral and basic substances in postmortem and antemortem whole blood using simple protein precipitation and UPLC-HR-TOF-MS

Forensic Science International

Volumn 266, Issue , 2016, Pages 453-461

  Telving, Rasmus ^a   Hasselstrøm, Jørgen Bo ^a   Andreasen, Mette Findal ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

DUID; High resolution mass spectrometry; Postmortem; Time of flight; Toxicological screening; Whole blood

Indexed keywords

3 HYDROXYBUTYRIC ACID; 4 HYDROXYBUTYRIC ACID; AMIODARONE; AMPHETAMINE; BROMAZEPAM; BROTIZOLAM; BUPRENORPHINE; CLOBAZAM; COCAINE; DIAZEPAM; DRUG; METHADONE; NORDAZEPAM; OXAZEPAM; PHENOBARBITAL; SALICYLIC ACID; TEMAZEPAM;

ARTICLE; AUTOPSY; BLOOD; BLOOD SAMPLING; CONTROLLED STUDY; ELECTROSPRAY; HUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN PRECIPITATION; RETENTION TIME; TIME OF FLIGHT MASS SPECTROMETRY; TOXICOLOGY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY HIGH RESOLUTION TIME OF FLIGHT MASS SPECTROMETRY; CHEMISTRY; DRUG DEPENDENCE; FORENSIC TOXICOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PH; PROCEDURES;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FORENSIC TOXICOLOGY; HUMANS; HYDROGEN-ION CONCENTRATION; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; SUBSTANCE-RELATED DISORDERS;

EID: 84989836778     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2016.07.004     Document Type: Article

References (51)

1. [1] Hino, Y., Ojanpera, I., Rasanen, I., Vuori, E., Performance of immunoassays in screening for opiates, cannabinoids and amphetamines in post-mortem blood. Forensic Sci. Int. 131 (2003), 148–155.
2. [2] George, S., Position of immunological techniques in screening in clinical toxicology. Clin. Chem. Lab. Med. 42 (2004), 1288–1309.
3. [3] Hans, K.P., Maurer, H., Weber, A.A., Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. 3rd revised and enlarged edition, 2007, Wiley, Weinheim.
4. [4] Herzler, M., Herre, S., Pragst, F., Selectivity of substance identification by HPLC-DAD in toxicological analysis using a UV spectra library of 2682 compounds. J. Anal. Toxicol. 27 (2003), 233–242.
5. [5] Kratzsch, C., Tenberken, O., Peters, F.T., Weber, A.A., Kraemer, T., Maurer, H.H., Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J. Mass Spectrom. 39 (2004), 856–872.
6. [6] Mueller, C.A., Weinmann, W., Dresen, S., Schreiber, A., Gergov, M., Development of a multi-target screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching. Rapid Commun. Mass Spectrom. 19 (2005), 1332–1338.
7. [7] Wissenbach, D.K., Meyer, M.R., Remane, D., Weber, A.A., Maurer, H.H., Development of the first metabolite-based LC–MS(n) urine drug screening procedure-exemplified for antidepressants. Anal. Bioanal. Chem. 400 (2011), 79–88.
8. n screening concept. Anal. Bioanal. Chem. 400 (2011), 3481–3489.
9. [9] Peters, F.T., Recent advances of liquid chromatography-(tandem) mass spectrometry in clinical and forensic toxicology. Clin. Biochem. 44 (2011), 54–65.
10. [10] Gergov, M., Boucher, B., Ojanpera, I., Vuori, E., Toxicological screening of urine for drugs by liquid chromatography/time-of-flight mass spectrometry with automated target library search based on elemental formulas. Rapid Commun. Mass Spectrom. 15 (2001), 521–526.
11. [11] Lee, H.K., Ho, C.S., Iu, Y.P., Lai, P.S., Shek, C.C., Lo, Y.C., Klinke, H.B., Wood, M., Development of a broad toxicological screening technique for urine using ultra-performance liquid chromatography and time-of-flight mass spectrometry. Anal. Chim. Acta 649 (2009), 80–90.
12. [12] Broecker, S., Herre, S., Wust, B., Zweigenbaum, J., Pragst, F., Development and practical application of a library of CID accurate mass spectra of more than 2,500 toxic compounds for systematic toxicological analysis by LC–QTOF-MS with data-dependent acquisition. Anal. Bioanal. Chem. 400 (2011), 101–117.
13. [13] Pelander, A., Decker, P., Baessmann, C., Ojanpera, I., Evaluation of a high resolving power time-of-flight mass spectrometer for drug analysis in terms of resolving power and acquisition rate. J. Am. Soc. Mass Spectrom. 22 (2011), 379–385.
14. [14] Birkler, R.I., Telving, R., Ingemann-Hansen, O., Charles, A.V., Johannsen, M., Andreasen, M.F., Screening analysis for medicinal drugs and drugs of abuse in whole blood using ultra-performance liquid chromatography time-of-flight mass spectrometry (UPLC-TOF-MS) – toxicological findings in cases of alleged sexual assault. Forensic Sci. Int. 222 (2012), 154–161.
15. [15] Marin, S.J., Hughes, J.M., Lawlor, B.G., Clark, C.J., McMillin, G.A., Rapid screening for 67 drugs and metabolites in serum or plasma by accurate-mass LC–TOF-MS. J. Anal. Toxicol. 36 (2012), 477–486.
16. [16] Dalsgaard, P.W., Rasmussen, B.S., Muller, I.B., Linnet, K., Toxicological screening of basic drugs in whole blood using UPLC-TOF-MS. Drug Test. Anal. 4 (2012), 313–319.
17. [17] de Castro, A., Gergov, M., Ostman, P., Ojanpera, I., Pelander, A., Combined drug screening and confirmation by liquid chromatography time-of-flight mass spectrometry with reverse database search. Anal. Bioanal. Chem. 403 (2012), 1265–1278.
18. [18] Ojanpera, I., Kolmonen, M., Pelander, A., Current use of high-resolution mass spectrometry in drug screening relevant to clinical and forensic toxicology and doping control. Anal. Bioanal. Chem. 403 (2012), 1203–1220.
19. [19] Dalsgaard, P.W., Rode, A.J., Pedersen, A.J., Rasmussen, B.S., Windberg, C.N., Linnet, K., Screening of 30 acidic and neutral pharmaceuticals in whole blood by fully automated SPE and UPLC-TOF-MS(E). Drug Test. Anal. 5 (2013), 254–258.
20. [20] Pedersen, A.J., Dalsgaard, P.W., Rode, A.J., Rasmussen, B.S., Muller, I.B., Johansen, S.S., Linnet, K., Screening for illicit and medicinal drugs in whole blood using fully automated SPE and ultra-high-performance liquid chromatography with TOF-MS with data-independent acquisition. J. Sep. Sci. 36 (2013), 2081–2089.
21. [21] Roman, M., Strom, L., Tell, H., Josefsson, M., Liquid chromatography/time-of-flight mass spectrometry analysis of postmortem blood samples for targeted toxicological screening. Anal. Bioanal. Chem. 405 (2013), 4107–4125.
22. [22] Sundstrom, M., Pelander, A., Angerer, V., Hutter, M., Kneisel, S., Ojanpera, I., A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal. Bioanal. Chem. 405 (2013), 8463–8474.
23. [23] Chindarkar, N.S., Wakefield, M.R., Stone, J.A., Fitzgerald, R.L., Liquid chromatography high-resolution TOF analysis: investigation of MSE for broad-spectrum drug screening. Clin. Chem. 60 (2014), 1115–1125.
24. [24] Sundstrom, M., Pelander, A., Simojoki, K., Ojanpera, I., Patterns of drug abuse among drug users with regular and irregular attendance for treatment as detected by comprehensive UHPLC-HR-TOF-MS. Drug Test. Anal. 8 (2016), 39–45.
25. [25] Sundstrom, M., Pelander, A., Ojanpera, I., Comparison between drug screening by immunoassay and ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry in post-mortem urine. Drug Test. Anal. 7 (2015), 420–427.
26. [26] Nielsen, K.L., Telving, R., Andreasen, M.F., Hasselstrom, J.B., Johannsen, M., A metabolomics study of retrospective forensic data from whole blood samples of humans exposed to 3,4-methylenedioxymethamphetamine: a new approach for identifying drug metabolites and changes in metabolism related to drug consumption. J. Proteome Res. 15 (2016), 619–627.
27. [27] Telving, R., Hasselstrom, J.B., Andreasen, M.F., Is THC-COOH-glucuronide a useful marker for tetrahydrocannabinol (THC) in DUID cases? Retrospective data analysis on UPLC-HR-TOFMS data files from 2 years of DUID cases. Congress Book 53rd TIAFT (International Association of Forensic Toxicologists) Meeting in Florence, Italy, 2015.
28. [28] Helfer, A.G., Michely, J.A., Weber, A.A., Meyer, M.R., Maurer, H.H., Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening – exemplified for cardiovascular drugs. Anal. Chim Acta. 891 (2015), 221–233.
29. [29] Holm, N.B., Pedersen, A.J., Dalsgaard, P.W., Linnet, K., Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test. Anal. 7 (2015), 199–206.
30. [30] Peters, F.T., Remane, D., Aspects of matrix effects in applications of liquid chromatography–mass spectrometry to forensic and clinical toxicology – a review. Anal. Bioanal. Chem. 403 (2012), 2155–2172.
31. [31] Broecker, S., Herre, S., Pragst, F., Kuhlmann, F., Wust, B., Zweigenbaum, J., Toxicological Screening with the Agilent 6500 Series Accurate-Mass Q-TOF LC/MS and the Personal Compound Database and Library using the Broecker, Herre and Pragst Accurate Mass Spectral Library. 2010, Agilent Technologies, Inc., USA.
32. E for Toxicology Screening. 2011, USA, Waters Corporation.
33. [33] Bruker ToxScreener™ – A Comprehensive Screening Solution for Forensic Toxicology. 2014, Bruker Daltonik GmbH, BrBremen, Germany.
34. [34] New Psychoactive Substances in Europe: An Update from the EU Early Warning System. March 2015. European Monitoring Centre for Drugs and Drug Addiction. 2015, Publication Office of the European Union, Luxembourg.
35. [35] Guale, F., Shahreza, S., Walterscheid, J.P., Chen, H.H., Arndt, C., Kelly, A.T., Mozayani, A., Validation of LC–TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. J. Anal. Toxicol. 37 (2013), 17–24.
36. [36] Sorensen, L.K., Hasselstrom, J.B., A high-throughput multi-class liquid chromatography tandem mass spectrometry method for quantitative determination of licit and illicit drugs in whole blood. Anal. Meth. 5 (2013), 3185–3193.
37. [37] Sorensen, L.K., Determination of acidic and neutral therapeutic drugs in human blood by liquid chromatography–electrospray tandem mass spectrometry. Forensic Sci. Int. 206 (2011), 119–126.
38. [38] Sorensen, L.K., Determination of metformin and other biguanides in forensic whole blood samples by hydrophilic interaction liquid chromatography–electrospray tandem mass spectrometry. Biomed. Chromatogr. 26 (2012), 1–5.
39. [39] Sorensen, L.K., Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography–electrospray tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 879 (2011), 727–736.
40. [40] Sorensen, L.K., A liquid chromatography–electrospray tandem mass spectrometry method for the determination of antiarrhythmic drugs and their metabolites in forensic whole blood samples. J. Anal. Toxicol. 36 (2012), 116–122.
41. [41] Sorensen, L.K., Hasselstrom, J.B., Simultaneous determination of propofol and its glucuronide in whole blood by liquid chromatography–electrospray tandem mass spectrometry and the influence of sample storage conditions on the reliability of the test results. J. Pharm. Biomed. Anal. 109 (2015), 158–163.
42. [42] Sorensen, L.K., Rittig, N.F., Holmquist, E.F., Jorgensen, K.A., Jorgensen, J.O.L., Moller, N., Johannsen, M., Simultaneous determination of beta-hydroxybutyrate and beta-hydroxy-beta-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry. Clin. Biochem. 46 (2013), 1877–1883.
43. [43] Sorensen, L.K., Hasselstrom, J.B., Determination of therapeutic gamma-aminobutyric acid analogs in forensic whole blood by hydrophilic interaction liquid chromatography–electrospray tandem mass spectrometry. J. Anal. Toxicol. 38 (2014), 177–183.
44. [44] Sorensen, L.K., Hasselstrom, J.B., A hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry method for the simultaneous determination of gamma-hydroxybutyrate and its precursors in forensic whole blood. Forensic Sci. Int. 222 (2012), 352–359.
45. [45] The International Association of Forensic Toxicologists (TIAFT), Reference Blood Level List of Therapeutic and Toxic Substances. 2013 Available from http://www.tiaft.org/ (accessed July 2013).
46. [46] Per se DUID Limits in Denmark. 2016 Available from https://www.retsinformation.dk/Forms/R0710.aspx?id=138271#B1 (accessed March 2016).
47. [47] Andreasen, M.F., Telving, R., Birkler, R.I., Schumacher, B., Johannsen, M., A fatal poisoning involving Bromo-Dragonfly. Forensic Sci. Int. 183 (2009), 91–96.
48. [48] Grubbs, F.E., Sample criteria for testing outlying observations. Ann. Math. Stat. 21 (1950), 27–58.
49. [49] Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS. Anal. Chem. 75 (2003), 3019–3030.
50. [50] Baselt, R.C., Disposition of Toxic Drug and Chemicals in Man. 10th ed., 2014, USA Biomedical Publications, Seal Beach, CA.
51. [51] Andreasen, M.F., Telving, R., Rosendal, I., Eg, M.B., Hasselstrom, J.B., Andersen, L.V., A fatal poisoning involving 25C-NBOMe. Forensic Sci. Int. 251 (2015), e1–e8.